
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.
Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.

